For the nine months ended Q3 FY December 2026, net sales were 527,808 thousand yen, operating loss was 1,104,482 thousand yen, ordinary loss was 1,112,040 thousand yen, and quarterly net loss was 1,115,090 thousand yen. Compared with the same quarter of the prior year, net sales increased and losses narrowed. No dividend forecast; full-year earnings forecast not disclosed due to difficulty in reasonable estimation. Capital increased due to exercise of stock acquisition rights. Supplementary materials to the financial summary provide detailed information on research and development activities.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4588-20261106-01.pdf","jir_short_summary":"For the nine months ended Q3 FY December 2026, net sales were 527,808 thousand yen, operating loss was 1,104,482 thousand yen, ordinary loss was 1,112,040 thousand yen, and quarterly net loss was 1,115,090 thousand yen. Compared with the same quarter of the prior year, net sales increased and losses narrowed. No dividend forecast; full-year earnings forecast not disclosed due to difficulty in reasonable estimation. Capital increased due to exercise of stock acquisition rights. Supplementary materials to the financial summary provide detailed information on research and development activities.","jir_summary":"### Summary of Results\nOncolys BioPharma Inc.'s Q3 for the fiscal year ending December 2026 posted net sales of 527,808 thousand yen, operating loss of 1,104,482 thousand yen, ordinary loss of 1,112,040 thousand yen, and quarterly net loss of 1,115,090 thousand yen. Net sales rose substantially year-on-year, while losses continued to be incurred. Progress in domestic and international product launches and clinical development are notable. Earnings forecasts were not disclosed due to difficulty in making reasonable estimates; forward-looking information is explained in the attached materials. Research and development expenses totaled 972,693 thousand yen, and the company reported an R&D organization of 26 people. Exercise of stock acquisition rights resulted in increases in capital stock and capital surplus, causing changes in the capital structure.\n\n### Outlook and Capital Trends\nWith no earnings forecast published, significant uncertainty remains. Revenues may be affected by domestic and international sales and milestone income related to OBP-301, development events such as OBP-601, and domestic commercialization of Telomelysin injections. The supplementary information in the financial summary details R&D progress, organization and pipeline status, and attention should be paid to milestone and license agreements as potential revenue sources. Capital increases due to exercised stock acquisition rights have occurred, so dilution should be monitored.","jir_financial_highlights":"Net Sales: 527,808 thousand yen (Approximately 0.0% YoY (prior year period: 28,546 thousand yen \u2192 527,808 thousand yen))\nOperating Loss: -1,104,482 thousand yen (Improved from -1,571,067 thousand yen in the prior year period)\nOrdinary Loss: -1,112,040 thousand yen (Improved from -1,614,576 thousand yen in the prior year period)\nQuarterly Net Loss: -1,115,090 thousand yen (Improved from -1,617,044 thousand yen in the prior year period)\nCash and Deposits: 2,989,959 thousand yen (Decreased compared with the end of the previous fiscal year)","jir_category":"","jir_hashtags":"#OncolysBioPharma, #FinancialResults, #ResearchAndDevelopmentTrends","jir_key_figures":"Net Sales: 527,808 thousand yen\nOperating Loss: -1,104,482 thousand yen\nQuarterly Net Loss: -1,115,090 thousand yen","jir_meta_title":"Oncolys BioPharma Inc. - FY2026 Q3 Financial Summary | Net Sales 527,808 thousand yen","jir_meta_description":"Key points from Oncolys BioPharma Inc.'s FY2026 Q3 financial summary: net sales and loss positions, dividend policy status, reasons for undisclosed earnings forecast, R&D activity updates, and summary of capital changes for investor reference.","jir_og_title":"Oncolys BioPharma Inc. | FY2026 Q3 Financial Summary","jir_og_description":"Oncolys BioPharma Inc. Q3 results: net sales 527,808 thousand yen, operating loss 1,104,482 thousand yen. Future outlook not disclosed; detailed R&D activities and capital movements provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-144032","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n